Result: S125: 10-day decitabine vs. conventional chemotherapy (“3 + 7”) followed by allografting (HSCT) in AML patients ≥60 years: a randomized phase III study of the EORTC Leukemia Group, GIMEMA, CELG, and GMDS-SG

*Title*:

*Author/editor-in-chief*:

*Publication*:

Freiburg : Universität, 2024

*Physical description scale*:

1 Online-Ressource

*Format*:

*eBook*

*Language*:

*eng*

*Notes*:

ISSN: 2572-9241

*DOI*:

10.1097/01.hs9.0000843392.61672.18

*Result*: S125: 10-day decitabine vs. conventional chemotherapy (“3 + 7”) followed by allografting (HSCT) in AML patients ≥60 years: a randomized phase III study of the EORTC Leukemia Group, GIMEMA, CELG, and GMDS-SG